Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Appendix B: Panel Roster and Financial Disclosures


Last Updated: September 1, 2014; Last Reviewed: September 1, 2014

Hepatitis B Virus Infection
Member Financial Disclosure
Company Relationship
Bhattacharya, Debika University of California, Los Angeles International Antiviral Society – USA Honoraria
Research Support
Jain, Mamta University of Texas Southwestern Medical Center
AbbVie Advisory Board, Research Support
Actelion Research Support
Boehringer Ingelheim Advisory Board, Research Support
Gilead Sciences Advisory Board, Research Support, Speaker's Bureau
GlaxoSmithKline Research Support
Theratechnologies Research Support
ViiV Research Support
Nunez, Marina Wake Forest University Health Sciences
Bristol-Myers Squibb
Research Support
Gilead Advisory Board
Peters, Marion* University of California, San Francisco Biotron Advisory Board
Genentech Other
GReD Spouse has relationship
International Antiviral Society (IAS-USA) Advisory Board
Johnson & Johnson
Thio, Chole Johns Hopkins University
None N/A

* Group lead

Note: Members were asked to disclose all relationships from 24 months prior to the updated date. The period of reporting was from September 1, 2012, through September 1, 2014.

Download Guidelines